Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2016 | Aug. 08, 2016 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Jun. 30, 2016 | |
Document Fiscal Year Focus | 2,016 | |
Document Fiscal Period Focus | Q2 | |
Entity Registrant Name | Moleculin Biotech, Inc. | |
Entity Central Index Key | 1,659,617 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Trading Symbol | MBRX | |
Entity Common Stock, Shares Outstanding | 11,254,756 |
Balance Sheets
Balance Sheets - USD ($) | Jun. 30, 2016 | Dec. 31, 2015 |
Current Assets: | ||
Cash and cash equivalents | $ 7,244,684 | $ 28,091 |
Prepaid expenses | 315,143 | 0 |
Total current assets | 7,559,827 | 28,091 |
Long-Term Assets: | ||
Furniture and equipment, net of accumulated depreciation | 7,168 | 0 |
Intangible assets, net of accumulated amortization | 11,666,404 | 0 |
Total Assets | 19,233,399 | 28,091 |
Current Liabilities: | ||
Accounts payable and accrued expenses | 721,103 | 322,790 |
Accounts payable and accrued expenses-related party | 250,000 | 0 |
Convertible notes payable | 431,644 | 450,000 |
Total current liabilities | 1,402,747 | 772,790 |
Long-term payable-related party | 600,000 | 0 |
Total Liabilities | 2,002,747 | 772,790 |
Stockholders' Equity (Deficit): | ||
Preferred stock, $0.001 par value; 5,000,000 authorized, no shares issued and outstanding | 0 | 0 |
Common stock, $0.001 par value; 75,000,000 authorized, 11,254,756 and 6,661,000 shares issued and outstanding, respectively | 11,255 | 6,661 |
Subscription receivable | (3,000) | (3,000) |
Additional paid-in capital | 19,298,614 | 0 |
Accumulated deficit | (2,076,217) | (748,360) |
Total Stockholders' Equity (Deficit) | 17,230,652 | (744,699) |
Total Liabilities and Stockholders' Equity (Deficit) | $ 19,233,399 | $ 28,091 |
Balance Sheets (Parenthetical)
Balance Sheets (Parenthetical) - $ / shares | Jun. 30, 2016 | Dec. 31, 2015 |
Preferred Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Preferred Stock, Shares Authorized | 5,000,000 | |
Preferred Stock, Shares Issued | 0 | 0 |
Preferred Stock, Shares Outstanding | 0 | 0 |
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 75,000,000 | |
Common Stock, Shares, Issued | 11,254,756 | 6,661,000 |
Common Stock, Shares, Outstanding | 11,254,756 | 6,661,000 |
Statements of Operations
Statements of Operations - USD ($) | 3 Months Ended | 6 Months Ended |
Jun. 30, 2016 | Jun. 30, 2016 | |
Revenue | $ 0 | $ 0 |
Operating expenses: | ||
Research and development | 361,728 | 376,728 |
General and administrative | 618,001 | 923,572 |
Depreciation | 652 | 652 |
Total operating expenses | 980,381 | 1,300,952 |
Loss from operations | (980,381) | (1,300,952) |
Other expense: | ||
Interest expense | (15,235) | (26,905) |
Net loss | $ (995,616) | $ (1,327,857) |
Net loss per common share - basic and diluted (in dollars per share) | $ (0.11) | $ (0.17) |
Weighted average common shares outstanding - basic and diluted (in shares) | 8,875,173 | 7,796,782 |
Statement of Cash Flows
Statement of Cash Flows | 6 Months Ended |
Jun. 30, 2016USD ($) | |
Cash Flows From Operating Activities: | |
Net loss | $ (1,327,857) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
Depreciation | 652 |
Amortization of intangible assets | 256,889 |
Stock-based compensation | 161,496 |
Changes in operating assets and liabilities: | |
Prepaid expenses | (315,143) |
Accounts payable and accrued expenses | (421,938) |
Net Cash Used In Operating Activities | (1,645,901) |
Cash Flows From Investing Activities: | |
Cash acquired through acquisition of Moleculin, LLC | 362 |
Net Cash Provided By Investing Activities | 362 |
Cash Flows From Financing Activities: | |
Proceeds from notes payable | 165,000 |
Payments on notes payable | (469,939) |
Proceeds from sale of common stock, net of direct offering costs | 9,167,071 |
Net Cash Provided By Financing Activities | 8,862,132 |
Net change in cash and cash equivalents | 7,216,593 |
Cash and cash equivalents, at beginning of period | 28,091 |
Cash and cash equivalents, at end of period | 7,244,684 |
Supplemental disclosures of cash flow information: | |
Cash paid for interest | 47,951 |
Cash paid for income taxes | 0 |
Supplemental disclosure of non-cash investing and financing activities: | |
Acquisition of intangible assets through accounts payable and long-term payable-related party | 850,000 |
Common stock issued to acquire intangible assets | 3,774,000 |
Common stock issued for conversion of debt | 201,055 |
Common stock issued for acquisition of Moleculin, LLC | $ 5,999,586 |
Description of Business and Sum
Description of Business and Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2016 | |
Accounting Policies [Abstract] | |
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] | Nature of Business Our lead drug candidate is liposomal Annamycin, which we refer to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia, or AML. In August 2015, the Company entered into a rights transfer agreement with AnnaMed, Inc. (“AnnaMed”), a company affiliated with certain members of the Company’s management and board of directors, pursuant to which, in exchange for 1,431,000 The Annamycin drug substance is no longer covered by any existing patent protection. We intend to submit patent applications for formulation, synthetic process and reconstitution related to our Annamycin drug product candidate, although there is no assurance that we will be successful in obtaining such patent protection. Independently from potential patent protection, we believe Annamycin will qualify for Orphan Drug status, which could entitle us to market exclusivity of up to 7 and 10 years from the date of approval of a New Drug Application (“NDA”) and Marketing Authorization (“MA”), in the US and the European Union (“EU”), respectively. However, there can be no assurance that such status will be granted. Separately, the FDA may also grant market exclusivity of up to five years for newly approved new chemical entities (of which Annamycin would be one), but there can be no assurance that such exclusivity will be granted or, if granted, for how long. We have two other drug development projects in progress, one involving a portfolio of small molecules, which we refer to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma (the most common form of brain tumor) in particular. We have been granted royalty-bearing, worldwide, exclusive licenses for the patent and technology rights related to our WP1066 Portfolio and WP1122 Portfolio drug technologies, as these patent rights are owned by MD Anderson. On August 11, 2015, the Company entered into a rights transfer agreement for WP1122 with IntertechBio Corporation (“IntertechBio”), a company affiliated with certain members of our management, whereby IntertechBio agreed to assign its license or sublicense its license to certain metabolic inhibitor technology owned by MD Anderson. In consideration, the Company issued 630,000 The Company filed a registration statement on Form S-1 (which was declared effective on May 2, 2016) with respect to the Company’s initial public offering of shares of its common stock (“IPO”) to fund the development of its technologies. Prior to the declaration of effectiveness of the registration statement on Form S-1, Moleculin, LLC (“Moleculin”) was merged with and into MBI, which survived the merger. Moleculin, LLC was the holder of a license agreement with MD Anderson covering technology referred to as the WP1066 Portfolio, which is focused on the modulation of key oncogenic transcription factors. Going Concern - 2,076,217 6,744,684 indicate that impairment exists. No material impairments of intangible assets have been identified during any of the periods presented. Intangible assets and goodwill are tested for impairment on an annual basis, and between annual tests if indicators of potential impairment exist, using a fair-value-based approach. Goodwill is not amortized and is not deductible for tax purposes. 2,691,803 200,000 107,802 Research and Development Costs - |
Intangible Assets
Intangible Assets | 6 Months Ended |
Jun. 30, 2016 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets Disclosure [Text Block] | Note 2 Intangible Assets June 30, December 31, Intangibles acquired from Moleculin, LLC $ 7,299,293 $ HPI license 4,624,000 Less: accumulated amortization (256,889) Intangible assets, net $ 11,666,404 $ Merger of Moleculin, LLC On May 2, 2016, Moleculin, LLC, a Texas limited liability company, was merged with and into the Company. As a result of the merger, the Company issued to the holders of Moleculin equity interests an aggregate of 999,931 5,999,586 57,822 As additional consideration payable to the Moleculin LLC unit holders, we agreed pursuant to the merger agreement that if drugs for dermatology indications are successfully developed by us (or our successors) using any of the Existing IP Assets, then the Moleculin LLC unit holders, in the aggregate, will be entitled to receive a 2.5 The acquisition price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date. Cash $ 362 Property & Equipment 7,820 Intangibles 7,299,293 Total assets acquired 7,307,475 Liabilities assumed (1,250,067) Net assets acquired/total consideration transferred $ 6,057,408 The Company is in the process of obtaining input from third-parties of its tangible and intangible assets and other information necessary to measure the fair value of the assets acquired and liabilities assumed; thus the provisional measurements of current assets, property and equipment, intangibles, and liabilities assumed are subject to change, which could be significant. We will finalize the amounts recognized as we obtain the information necessary to complete the analysis. We expect to finalize these amounts as soon as possible but no later than one year from the acquisition date. The Company has not recorded any amortization expense related to the intangible assets acquired from the Moleculin acquisition for the three and six months ended June 30, 2016 as the Company is still in the process of determining the fair value of the intangible assets acquired. The following table presents the unaudited condensed pro forma results of operations that reflect the acquisition of Moleculin as if the acquisition had occurred as of January 1, 2016, adjusted for items that are directly attributable to the acquisition with the exception of the amortization for intangible assets acquired. For the three For the six Total operating expenses $ (1,018,579) $ (1,446,394) Net loss $ (1,039,059) $ (1,558,839) Net loss per common share basic and diluted $ (0.11) $ (0.18) Weighted average outstanding common shares basic and diluted 9,215,150 8,466,736 License - Houston Pharmaceuticals, Inc. Our acquisition of Moleculin, LLC, occurring prior to our IPO offering, provided us with the rights to the license agreement that Moleculin, LLC had with MD Anderson covering the WP1066 Portfolio. However, Moleculin, LLC had previously granted Houston Pharmaceuticals, Inc. (“HPI”) an option to obtain an exclusive sub-license to develop the WP1066 Portfolio in all non-dermatological fields. On May 2, 2016 and in connection with the acquisition of Moleculin, LLC and our IPO, we entered into two agreements with HPI. The first agreement terminated HPI’s option to obtain the aforementioned exclusive sublicense in exchange for a payment of $ 100,000 629,000 750,000 1.0 1.0 We have reflected the issuance of the 629,000 common stock which was valued at $ 3,774,000 250,000 600,000 The license asset is being amortized over 3 256,889 |
Convertible Notes Payable
Convertible Notes Payable | 6 Months Ended |
Jun. 30, 2016 | |
Convertible Notes Payable Abstract [Abstract] | |
Convertible Notes Payable Disclosure [Text Block] | Note 3 Convertible Notes Payable On various dates from August 31, 2015 through January 19, 2016, each as amended on March 10, 2016, the Company entered into seven unsecured promissory notes with three separate third party investors. Each note bears interest at 8.0 However, since the completion of the IPO occurred prior to June 30, 2016, these notes were to be automatically converted according to their terms into shares of the Company’s common stock at applicable conversion price upon the Company’s IPO to the extent and provided that no holder of these notes was or will be permitted to convert such notes to the extent that the holder or any of its affiliates would beneficially own in excess of 4.99 The IPO was completed on May 31, 2016. On May 31, 2016, pursuant to the conversion feature of the foregoing notes and with restriction of the 4.99% beneficially owned condition limitation, the Company issued 1,166,503 183,356 17,699 2,691,803 The convertible notes were analyzed for a beneficial conversion feature on various issuance dates, at which time it was concluded that a beneficial conversion feature did not exist. Issuance Date June 30, 2016 December 31, Conversion Rate Shares August 31, 2015* $ 72,753 $ 125,000 $ 0.1299 560,068 September 3, 2015 125,000 125,000 0.1299 962,279 October 4, 2015* 68,891 147,000 0.20 344,456 October 4, 2015** 3,000 0.20 October 28, 2015** 50,000 0.20 January 14, 2016 82,500 0.20 412,500 January 19, 2016 82,500 0.20 412,500 Total $ 431,644 $ 450,000 2,691,803 * Debt partially converted on May 31, 2016. ** Debt fully converted to common shares on May 31, 2016. The common shares relating to the above mentioned convertible notes payable contain the following trading restrictions: (a) beginning 90 days after the initial closing of our IPO and until the one-year anniversary of the initial closing of the IPO, the holder of the note will be able to sell 1% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the note can sell up to 3% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (c) if the common stock price is over $10.00 per share for five consecutive trading days then the holder of the note can sell up to an additional 5% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 7% of the daily volume; and (d) if the common stock price is over $14.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock price falls back below $14.00 per share; and (b) thereafter, until the two-year anniversary of the initial closing of IPO, the holder of the note can sell on any trading day 10% of the daily volume; provided that if the common stock price is over $10.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock falls back below $10.00 per share. The foregoing lock-up restrictions relate to public sales and do not restrict the transfer of the shares privately, if permitted by applicable law, provided the acquirer of the shares agrees to comply with the above restrictions with respect to any public sales. |
Equity
Equity | 6 Months Ended |
Jun. 30, 2016 | |
Equity [Abstract] | |
Stockholders' Equity Note Disclosure [Text Block] | Note 4 Equity On May 2, 2016, the Company amended and restated its certificate of incorporation to increase the number of shares issuable to 80,000,000 5,000,000 75,000,000 Preferred Stock We are authorized to issue up to 5,000,000 shares of preferred stock. Our certificate of incorporation authorizes the board to issue these shares in one or more series, to determine the designations and the powers, preferences and relative, participating, optional or other special rights and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights (including the number of votes per share), redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series. As of June 30, 2016, there was no designated preferred stock. Common Stock On May 31, 2016, the Company completed its IPO and sold 1,540,026 6.00 8,464,183 107,802 5 7.50 374,763 1.39 5 80.61 In August 2015, the Company agreed to issue 4,600,000 4,600 3,000 During the period from January 1, 2016 through May 2, 2016, the Company sold 234,296 702,888 These shares are subject to the following lock-up agreement, from and after the later of six months after issuance or 90 days from the effective date of our IPO registration statement until the one-year anniversary thereof, (a) the holder of the shares can sell up to 10% of the purchased shares per month, subject to a maximum sale on any trading day of 8% of the daily volume of the common stock; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the shares can sell up to 20% of the purchased shares per month, subject to a maximum sale on any trading day of 10% of the daily volume of the common stock; and (c) if the common stock price is over $12.00 per share then the holder of the shares is not restricted from making any sales until such time as the common stock price falls back below $12.00 per share. On June 20, 2016, the Company agreed to issue 24,000 157,688 Adoption of 2015 Stock Plan On December 5, 2015, the Board of Directors of the Company approved the Company’s 2015 Stock Plan, which was amended on April 22, 2016. The expiration date of the plan is December 5, 2025 2,500,000 As of June 30, 2016, the Company has options to purchase 200,000 0.20 9.5 1,286,000 50,000 3,808 23,582 |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2016 | |
Income Tax Disclosure [Abstract] | |
Income Tax Disclosure [Text Block] | Note 5 - Income Taxes As of June 30, 2016, the Company had an operating loss carry forward of approximately $ 1,700,000 2035 |
Commitments and contingencies
Commitments and contingencies | 6 Months Ended |
Jun. 30, 2016 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | Note 6 Commitments and contingencies MD Anderson IntertechBio Agreement On August 11, 2015, the Company acquired the rights and obligations under the Patent and Technology License Agreement entered into between IntertechBio and MD Anderson dated April 2, 2012. Pursuant to the agreement, IntertechBio obtained a royalty-bearing, worldwide, exclusive license to intellectual property including patent rights related to the Company’s drug product candidate, WP1122. Under the agreement, IntertechBio agreed to pay annual maintenance fee in the amount of $ 10,000 20,000 40,000 60,000 80,000 100,000 200,000 400,000 600,000 Phase Amount Commencement of Phase II Study for a licensed product $ 200,000 Commencement of Phase III Study for a licensed product $ 250,000 Filing of a New Drug Application for a licensed product $ 400,000 Receipt of market approval for a licensed product $ 500,000 Per the October 2015 amendment to the agreement, MD Anderson has the right to terminate the license agreement if (i) a preclinical toxicology program for a licensed product is not initiated within one year of the effective date of the amendment, (ii) an investigational new drug application is not filed with the Food and Drug Administration for a Phase I study for a licensed product within three years of the effective date of the amendment, or (iii) a Phase I study for a licensed product is not commenced within five years of the effective date of the amendment. The agreement will expire upon the expiration of the licensed intellectual property. The rights obtained by the Company pursuant to the agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. All out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining the licensed patents have been and shall continue to be assumed by the Company. On October 8, 2015, IntertechBio Corporation entered into a letter agreement with MD Anderson wherein MD Anderson agreed to receive past due maintenance fees and patent expenses of $ 98,108 65,504 98,108 65,504 45,000 42,504 64,004 44,004 MD Anderson Patent & Technology License Agreement Upon the Company’s acquisition of Moleculin, LLC on May 2, 2016, we obtained a royalty-bearing, worldwide, exclusive license to intellectual property rights, including patent rights related to our WP1066 drug product candidate from MD Anderson through a Patent and Technology License Agreement Moleculin, LLC entered with MD Anderson on June 21, 2010 (the “Moleculin License Agreement”). Under the Moleculin License Agreement, Moleculin, LLC obtained the right to manufacture, have manufactured, use, import, offer to sell or sell products worldwide for any indication under the licensed intellectual property with the right to sublicense. In consideration, Moleculin, LLC agreed to make payments to MD Anderson including an up-front payment, milestone payments and minimum annual royalty payments for sales of products developed under the license agreement. Specifically, under the Moleculin License Agreement, Moleculin, LLC agreed to pay a nonrefundable upfront documentation fee; annual maintenance fee in the amount of $ 20,000 10,000 100,000 200,000 Upon completion of our acquisition of Moleculin, LLC, we assumed the rights and obligations of Moleculin, LLC. However, the rights we have obtained pursuant to the assignment of the Moleculin License Agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. All out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining the licensed patents have been and shall continue to be assumed by us. On October 8, 2015, Moleculin, LLC entered into a letter agreement with MD Anderson for Moleculin, LLC’s past due fees to MD Anderson in the amount of $ 691,186 300,000 125,000 175,000 91,186 125,000 On October 19, 2015, the agreement was amended for the milestone payments. The amended milestone payments are as follows: (i) commencement of Phase III Study for first licensed drug/product within the United States, Europe, China or Japan - $150,000; (ii) submission of the first NDA within the United States - $500,000; and (iii) receipt of first marketing approval for sale of a license product in the United States $600,000. On January 28, 2016, the Company and Moleculin, LLC entered into a letter agreement with MD Anderson where MD Anderson agreed to receive the remaining outstanding amount on or before the earlier of April 30, 2016 or four days after our IPO. This date was amended and per the amended agreement, the Company paid the outstanding Moleculin, LLC fees on May 31, 2016 in the amount of $ 306,186 Bonwick Capital Partners LLC On January 22, 2016, as amended on February 15, 2016, the Company entered into a letter agreement with Bonwick Capital Partners LLC. (“Bonwick”) to engage Bonwick as an exclusive financial advisor of the Company. Pursuant to the agreement, the Company agreed to: a) pay success fees equal to 7 7 125 25,000 100,000 50,000 Bonwick shall be entitled to a success fee as set forth above if the Company completes a financing with parties introduced by Bonwick prior to the termination agreement or during the 6 month period following the termination of the agreement. In connection with the Company’s IPO, Bonwick received a success fee of $ 646,872 107,802 7.50 6,266 Houston Pharmaceuticals, Inc. Our acquisition of Moleculin, LLC, occuring prior to our IPO offering, provided us with the rights of the license agreement that Moleculin, LLC had with MD Anderson covering the WP1066 Portfolio. As discussed in Note 2, we agreed to make payments to HPI of $ 750,000 1.0 |
Description of Business and S12
Description of Business and Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2016 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation - Unaudited Interim Financial Information |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates in Financial Statement Presentation - |
Business Combinations Policy [Policy Text Block] | Acquisition - |
Going Concern, Policy [Policy Text Block] | Going Concern - 2,076,217 |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents - 6,744,684 |
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] | Intangible assets - indicate that impairment exists. No material impairments of intangible assets have been identified during any of the periods presented. Intangible assets and goodwill are tested for impairment on an annual basis, and between annual tests if indicators of potential impairment exist, using a fair-value-based approach. Goodwill is not amortized and is not deductible for tax purposes. |
Debt Instrument, Convertible, Beneficial Conversion Feature Policy [Policy Text Block] | Beneficial Conversion Feature |
Income Tax, Policy [Policy Text Block] | Income Taxes - |
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | Stock-based Compensation - |
Earnings Per Share, Policy [Policy Text Block] | 2,691,803 200,000 107,802 |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Costs - |
Subsequent Events, Policy [Policy Text Block] | Subsequent Events - |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements - |
Intangible Assets (Tables)
Intangible Assets (Tables) | 6 Months Ended |
Jun. 30, 2016 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets Disclosure [Text Block] | Intangible assets consisted of the following at June 30, 2015 and December 31, 2015: June 30, December 31, Intangibles acquired from Moleculin, LLC $ 7,299,293 $ HPI license 4,624,000 Less: accumulated amortization (256,889) Intangible assets, net $ 11,666,404 $ |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] | The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date. Cash $ 362 Property & Equipment 7,820 Intangibles 7,299,293 Total assets acquired 7,307,475 Liabilities assumed (1,250,067) Net assets acquired/total consideration transferred $ 6,057,408 |
Business Acquisition, Pro Forma Information [Table Text Block] | This information has been compiled from historical financial statements and is not necessarily indicative of the results that actually would have been achieved had the transaction already occurred or that may be achieved in the future. For the three For the six Total operating expenses $ (1,018,579) $ (1,446,394) Net loss $ (1,039,059) $ (1,558,839) Net loss per common share basic and diluted $ (0.11) $ (0.18) Weighted average outstanding common shares basic and diluted 9,215,150 8,466,736 |
Convertible Notes Payable (Tabl
Convertible Notes Payable (Tables) | 6 Months Ended |
Jun. 30, 2016 | |
Convertible Notes Payable Abstract [Abstract] | |
Convertible Debt [Table Text Block] | The table below represents the shares that are convertible at June 30, 2016 relating to the principal amounts of these convertible notes payable and excludes any shares that are convertible relating to the associated accrued interest: Issuance Date June 30, 2016 December 31, Conversion Rate Shares August 31, 2015* $ 72,753 $ 125,000 $ 0.1299 560,068 September 3, 2015 125,000 125,000 0.1299 962,279 October 4, 2015* 68,891 147,000 0.20 344,456 October 4, 2015** 3,000 0.20 October 28, 2015** 50,000 0.20 January 14, 2016 82,500 0.20 412,500 January 19, 2016 82,500 0.20 412,500 Total $ 431,644 $ 450,000 2,691,803 * Debt partially converted on May 31, 2016. ** Debt fully converted to common shares on May 31, 2016. |
Commitments and contingencies (
Commitments and contingencies (Tables) | 6 Months Ended |
Jun. 30, 2016 | |
Commitments and Contingencies Disclosure [Abstract] | |
Patent And Technology License Agreement, Milestone Payments [Table Text Block] | Pursuant to an amendment on October 19, 2015, the Company will pay milestone payments as follows: Phase Amount Commencement of Phase II Study for a licensed product $ 200,000 Commencement of Phase III Study for a licensed product $ 250,000 Filing of a New Drug Application for a licensed product $ 400,000 Receipt of market approval for a licensed product $ 500,000 |
Description of Business and S16
Description of Business and Summary of Significant Accounting Policies (Details Textual) - USD ($) | 1 Months Ended | 6 Months Ended | |
Aug. 31, 2015 | Jun. 30, 2016 | Dec. 31, 2015 | |
Description Of Business And Summary Of Significant Accounting Policies [Line Items] | |||
Retained Earnings (Accumulated Deficit), Total | $ (2,076,217) | $ (748,360) | |
Cash, Uninsured Amount | $ 6,744,684 | ||
Warrant [Member] | |||
Description Of Business And Summary Of Significant Accounting Policies [Line Items] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 107,802 | ||
Employee Stock Option [Member] | |||
Description Of Business And Summary Of Significant Accounting Policies [Line Items] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 200,000 | ||
Convertible Debt Securities [Member] | |||
Description Of Business And Summary Of Significant Accounting Policies [Line Items] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 2,691,803 | ||
Use Rights [Member] | AnnaMed, Inc [Member] | |||
Description Of Business And Summary Of Significant Accounting Policies [Line Items] | |||
Stock Issued During Period, Shares, Purchase of Assets | 1,431,000 | ||
Use Rights [Member] | IntertechBio Corporation [Member] | |||
Description Of Business And Summary Of Significant Accounting Policies [Line Items] | |||
Stock Issued During Period, Shares, Purchase of Assets | 630,000 |
Intangible Assets (Details)
Intangible Assets (Details) - USD ($) | Jun. 30, 2016 | Dec. 31, 2015 |
Business Combination Segment Allocation [Line Items] | ||
Less: accumulated amortization | $ (256,889) | $ 0 |
Intangible assets, net | 11,666,404 | 0 |
Licensing Agreements [Member] | ||
Business Combination Segment Allocation [Line Items] | ||
Finite-Lived Intangible Assets, Gross | 4,624,000 | 0 |
Other Intangible Assets [Member] | ||
Business Combination Segment Allocation [Line Items] | ||
Finite-Lived Intangible Assets, Gross | $ 7,299,293 | $ 0 |
Intangible Assets (Details 1)
Intangible Assets (Details 1) - USD ($) | Jun. 30, 2016 | May 31, 2016 |
Business Combination Segment Allocation [Line Items] | ||
Liabilities assumed | $ (1,000,000) | |
Moleculin LLC [Member] | ||
Business Combination Segment Allocation [Line Items] | ||
Cash | $ 362 | |
Property & Equipment | 7,820 | |
Intangibles | 7,299,293 | |
Total assets acquired | 7,307,475 | |
Liabilities assumed | (1,250,067) | |
Net assets acquired/total consideration transferred | $ 6,057,408 |
Intangible Assets (Details 2)
Intangible Assets (Details 2) - USD ($) | 3 Months Ended | 6 Months Ended |
Jun. 30, 2016 | Jun. 30, 2016 | |
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] | ||
Total operating expenses | $ (1,018,579) | $ (1,446,394) |
Net loss | $ (1,039,059) | $ (1,558,839) |
Net loss per common share - basic and diluted (in dollars per share) | $ (0.11) | $ (0.18) |
Weighted average outstanding common shares - basic and diluted (in shares) | 9,215,150 | 8,466,736 |
Intangible Assets (Details Text
Intangible Assets (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 4 Months Ended | 6 Months Ended | |
May 31, 2016 | Jun. 30, 2016 | May 02, 2016 | Jun. 30, 2016 | Dec. 31, 2015 | |
Indefinite-lived Intangible Assets [Line Items] | |||||
Stock Issued During Period, Shares, New Issues | 234,296 | ||||
Accounts Payable, Related Parties, Current | $ 250,000 | $ 250,000 | $ 0 | ||
Amortization of Intangible Assets | 256,889 | ||||
Houston Pharmaceuticals, Inc [Member] | Licensing Agreements [Member] | |||||
Indefinite-lived Intangible Assets [Line Items] | |||||
Stock Issued During Period, Value, Acquisitions | 3,774,000 | ||||
Accounts Payable, Related Parties, Current | 250,000 | 250,000 | |||
Notes Payable, Related Parties, Noncurrent | $ 600,000 | $ 600,000 | |||
Finite-Lived Intangible Asset, Useful Life | 3 years | 3 years | |||
Amortization of Intangible Assets | $ 256,889 | $ 256,889 | |||
Moleculin LLC [Member] | |||||
Indefinite-lived Intangible Assets [Line Items] | |||||
Notes Receivable, Related Parties | $ 57,822 | ||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | $ 6,000,000 | ||||
Royalty On Net Revenues | 2.50% | ||||
Moleculin LLC [Member] | License Agreement [Member] | Houston Pharmaceuticals, Inc [Member] | |||||
Indefinite-lived Intangible Assets [Line Items] | |||||
Stock Issued During Period, Shares, New Issues | 629,000 | ||||
Accrued license agreement payment | $ 100,000 | ||||
Moleculin LLC [Member] | Out-Lincense Agreement [Member] | Houston Pharmaceuticals, Inc [Member] | |||||
Indefinite-lived Intangible Assets [Line Items] | |||||
Licencing Arrangements Consideration Payable | $ 750,000 | ||||
Licencing Arrangements Reserve | 1,000,000 | ||||
Payments to Acquire Intangible Assets | $ 1,000,000 | ||||
Common Stock [Member] | Moleculin LLC [Member] | |||||
Indefinite-lived Intangible Assets [Line Items] | |||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 999,931 | ||||
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned | $ 5,999,586 |
Convertible Notes Payable (Deta
Convertible Notes Payable (Details) - USD ($) | 6 Months Ended | ||
Jun. 30, 2016 | Dec. 31, 2015 | ||
Convertible Notes Payable, Current | $ 431,644 | $ 450,000 | |
Debt Instrument, Convertible, Number of Common Shares | 2,691,803 | ||
Investor A [Member] | Issue Date August 31 2015 [Member] | |||
Debt Instrument, Issuance Date | [1] | Aug. 31, 2015 | |
Convertible Notes Payable, Current | [1] | $ 72,753 | 125,000 |
Debt Instrument, Convertible, Conversion Price | [1] | $ 0.1299 | |
Debt Instrument, Convertible, Number of Common Shares | [1] | 560,068 | |
Investor A [Member] | Issue Date September 03 2015 [Member] | |||
Debt Instrument, Issuance Date | Sep. 3, 2015 | ||
Convertible Notes Payable, Current | $ 125,000 | 125,000 | |
Debt Instrument, Convertible, Conversion Price | $ 0.1299 | ||
Debt Instrument, Convertible, Number of Common Shares | 962,279 | ||
Investor B [Member] | Issue Date October 04 2015 One [Member] | |||
Debt Instrument, Issuance Date | [1] | Oct. 4, 2015 | |
Convertible Notes Payable, Current | [1] | $ 68,891 | 147,000 |
Debt Instrument, Convertible, Conversion Price | [1] | $ 0.2 | |
Debt Instrument, Convertible, Number of Common Shares | [1] | 344,456 | |
Investor C [Member] | Issue Date October 04 2015 Two [Member] | |||
Debt Instrument, Issuance Date | [2] | Oct. 4, 2015 | |
Convertible Notes Payable, Current | [2] | $ 0 | 3,000 |
Debt Instrument, Convertible, Conversion Price | [2] | $ 0.2 | |
Debt Instrument, Convertible, Number of Common Shares | [2] | 0 | |
Investor D [Member] | Issue Date October 28 2015 [Member] | |||
Debt Instrument, Issuance Date | [2] | Oct. 28, 2015 | |
Convertible Notes Payable, Current | [2] | $ 0 | 50,000 |
Debt Instrument, Convertible, Conversion Price | [2] | $ 0.2 | |
Debt Instrument, Convertible, Number of Common Shares | [2] | 0 | |
Investor D [Member] | Issue Date January 19 2016 [Member] | |||
Debt Instrument, Issuance Date | Jan. 19, 2016 | ||
Convertible Notes Payable, Current | $ 82,500 | 0 | |
Debt Instrument, Convertible, Conversion Price | $ 0.2 | ||
Debt Instrument, Convertible, Number of Common Shares | 412,500 | ||
Investor E [Member] | Issue Date January 14 2016 [Member] | |||
Debt Instrument, Issuance Date | Jan. 14, 2016 | ||
Convertible Notes Payable, Current | $ 82,500 | $ 0 | |
Debt Instrument, Convertible, Conversion Price | $ 0.2 | ||
Debt Instrument, Convertible, Number of Common Shares | 412,500 | ||
[1] | Debt partially converted on May 31, 2016. | ||
[2] | Debt fully converted to common shares on May 31, 2016. |
Convertible Notes Payable (De22
Convertible Notes Payable (Details Textual) - USD ($) | 1 Months Ended | 6 Months Ended |
May 31, 2016 | Jun. 30, 2016 | |
Debt Conversion, Converted Instrument, Common Stock Shares Issued Trading Restrictions Description | (a) beginning 90 days after the initial closing of our IPO and until the one-year anniversary of the initial closing of the IPO, the holder of the note will be able to sell 1% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the note can sell up to 3% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 4% of the daily volume; (c) if the common stock price is over $10.00 per share for five consecutive trading days then the holder of the note can sell up to an additional 5% of the number of shares of common stock underlying the note on a monthly basis, subject to a maximum sale on any trading day of 7% of the daily volume; and (d) if the common stock price is over $14.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock price falls back below $14.00 per share; and (b) thereafter, until the two-year anniversary of the initial closing of IPO, the holder of the note can sell on any trading day 10% of the daily volume; provided that if the common stock price is over $10.00 per share then the holder of the note is not restricted from making any sales until such time as the common stock falls back below $10.00 per share. The foregoing lock-up restrictions relate to public sales and do not restrict the transfer of the shares privately, if permitted by applicable law, provided the acquirer of the shares agrees to comply with the above restrictions with respect to any public sales. | |
Debt Conversion, Converted Instrument, Shares Issued | 1,166,503 | |
Debt Conversion, Original Debt, Amount | $ 183,356 | |
Interest Payable, Current | $ 17,699 | |
IPO [Member] | ||
Equity Method Investment, Ownership Percentage | 4.99% | |
Debt Conversion, Converted Instrument, Additional Shares Issued | 2,691,803 | |
Unsecured Promissory Notes [Member] | ||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% |
Equity (Details Textual)
Equity (Details Textual) - USD ($) | 1 Months Ended | 4 Months Ended | 6 Months Ended | ||||
Jun. 20, 2016 | May 31, 2016 | Apr. 22, 2016 | May 02, 2016 | Jun. 30, 2016 | Dec. 31, 2015 | Aug. 31, 2015 | |
Class of Stock [Line Items] | |||||||
Stock Issued During Period, Shares, New Issues | 234,296 | ||||||
Stock Issued During Period, Value, New Issues | $ 702,888 | ||||||
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable | $ 3,000 | $ 3,000 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date | Dec. 5, 2025 | ||||||
Common Stock, Shares Authorized | 75,000,000 | 75,000,000 | |||||
Share-based Compensation, Total | $ 161,496 | ||||||
Class of Warrant or Right, Period from which Warrants or Rights Exercisable | 5 years | ||||||
Proceeds from Issuance Initial Public Offering | $ 9,167,071 | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 107,802 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 7.50 | ||||||
Common Stock Lock-Up and Leak-Out Agreements Description | These shares are subject to the following lock-up agreement, from and after the later of six months after issuance or 90 days from the effective date of our IPO registration statement until the one-year anniversary thereof, (a) the holder of the shares can sell up to 10% of the purchased shares per month, subject to a maximum sale on any trading day of 8% of the daily volume of the common stock; (b) if the common stock price is over $7.00 per share for five consecutive trading days then the holder of the shares can sell up to 20% of the purchased shares per month, subject to a maximum sale on any trading day of 10% of the daily volume of the common stock; and (c) if the common stock price is over $12.00 per share then the holder of the shares is not restricted from making any sales until such time as the common stock price falls back below $12.00 per share. | ||||||
Shares Authorized | 80,000,000 | ||||||
Preferred Stock, Shares Authorized | 5,000,000 | 5,000,000 | |||||
PCG Advisory Group [Member] | |||||||
Class of Stock [Line Items] | |||||||
Stock Issued During Period, Shares, Issued for Services | 24,000 | ||||||
Stock Issued During Period, Value, Issued for Services | $ 157,688 | ||||||
Warrant [Member] | |||||||
Class of Stock [Line Items] | |||||||
Warrants Not Settleable in Cash, Fair Value Disclosure | $ 374,763 | ||||||
Fair Value Inputs, Discount Rate | 1.39% | ||||||
Fair Value Assumptions, Expected Term | 5 years | ||||||
Fair Value Assumptions, Expected Volatility Rate | 80.61% | ||||||
Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||||
IPO [Member] | |||||||
Class of Stock [Line Items] | |||||||
Stock Issued During Period, Shares, New Issues | 1,540,026 | ||||||
Shares Issued, Price Per Share | $ 6 | ||||||
Proceeds from Issuance Initial Public Offering | $ 8,464,183 | ||||||
2015 Stock Plan [Member] | |||||||
Class of Stock [Line Items] | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 2,500,000 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | 200,000 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ 0.20 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 9 years 6 months | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | $ 1,286,000 | ||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $ 23,582 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | 50,000 | ||||||
Director And Officers [Member] | |||||||
Class of Stock [Line Items] | |||||||
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable | $ 3,000 | ||||||
Common Stock, Shares Authorized | 4,600,000 | ||||||
Common Stock, Value, Subscriptions | $ 4,600 |
Income Taxes (Details Textual)
Income Taxes (Details Textual) | 3 Months Ended |
Jun. 30, 2016USD ($) | |
Operating Loss Carryforwards [Line Items] | |
Operating Loss Carryforwards | $ 1,700,000 |
Operating Loss Carryforwards Expiration Period | 2,035 |
Commitments and contingencies25
Commitments and contingencies (Details) | Jun. 30, 2016USD ($) |
Commencement Of Phase II Study For a Licensed Product [Member] | |
Commitments and Contingencies [Line Items] | |
Milestone Payments Liabilities | $ 200,000 |
Commencement Of Phase III Study For a Licensed Product [Member] | |
Commitments and Contingencies [Line Items] | |
Milestone Payments Liabilities | 250,000 |
Filing Of a New Drug Application For a Licensed Product [Member] | |
Commitments and Contingencies [Line Items] | |
Milestone Payments Liabilities | 400,000 |
Receipt Of Market Approval For a Licensed Product [Member] | |
Commitments and Contingencies [Line Items] | |
Milestone Payments Liabilities | $ 500,000 |
Commitments and contingencies26
Commitments and contingencies (Details Textual) - USD ($) | May 02, 2016 | Nov. 02, 2015 | Oct. 08, 2015 | May 31, 2016 | Feb. 29, 2016 | Jun. 30, 2016 | Apr. 30, 2016 | Jan. 31, 2016 | Dec. 31, 2015 | Oct. 31, 2015 | Aug. 31, 2015 |
Loss Contingencies [Line Items] | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 107,802 | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 7.50 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | $ 1,000,000 | ||||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | 750,000 | ||||||||||
Moleculin LLC [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Payments for Other Fees | 306,186 | ||||||||||
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities | $ 1,250,067 | ||||||||||
Patent Law Firm [Member] | Minimum Fee and patent Expenses [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Contractual Obligation, Total | $ 42,504 | $ 65,504 | |||||||||
Bonwick Capital Partners LLC [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Letter Agreements Terms | the Company agreed to: a) pay success fees equal to 7% of the gross proceeds from any form of financing; and b) issue five-year warrants to purchase 7% of the Company’s equity securities sold with a cashless exercise provision, exercisable at 125% of the price per share of the Company’s common stock paid by investors in the transaction. In addition, the Company agreed to reimburse Bonwick for all of its out-of-pocket expenses incurred in connection with the offering, not to exceed $25,000, and fees and expenses of their counsel not to exceed $100,000. | ||||||||||
Success Fee Percentage | 7.00% | ||||||||||
Class of Warrant or Right, Percentage of Securities Called by Warrants or Rights | 7.00% | ||||||||||
Class of Warrant or Right, Exercise Price Percentage Threshold | 125.00% | ||||||||||
Payments for Underwriting Expense | $ 50,000 | ||||||||||
Bonwick Capital Partners LLC [Member] | IPO [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Reimburement of Expenses | 6,266 | ||||||||||
Payments of Stock Issuance Costs | $ 646,872 | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 107,802 | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 7.50 | ||||||||||
Bonwick Capital Partners LLC [Member] | Maximum [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Reimbursement Payable, Offering Costs | 25,000 | ||||||||||
Reimbursement Payable, Fees and Expenses of Counsel | $ 100,000 | ||||||||||
Intertech Bio INC [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Payments for Royalties | $ 64,004 | ||||||||||
MD Anderson [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Payments for Royalties | $ 44,004 | ||||||||||
MD Anderson [Member] | Minimum Fee and patent Expenses [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Contractual Obligation, Total | $ 98,108 | $ 45,000 | 98,108 | ||||||||
MD Anderson [Member] | Minimum Annual Royalty [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Contractual Obligation, Total | 65,504 | ||||||||||
Patent and Technology License Agreement [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Contractual Obligation, Total | $ 91,186 | $ 175,000 | $ 125,000 | ||||||||
Payments for Royalties | $ 125,000 | ||||||||||
License Agreement, Maintenance Fee | $ 20,000 | ||||||||||
License Agreement, Maintenance Fee Annual Increase | 10,000 | ||||||||||
Payments for Other Fees | 300,000 | ||||||||||
License Agreement, Maintenance Fee - Maximum Payable Per Year | 100,000 | ||||||||||
Patent and Technology License Agreement [Member] | First Sale of Licensed Product [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Contractual Obligation Minimum Annual Royalty Payment Due After First Sale | $ 200,000 | ||||||||||
Patent and Technology License Agreement [Member] | Servicing Fee payable [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Contractual Obligation, Due First Anniversary April 2, 2013 | $ 10,000 | ||||||||||
Contractual Obligation, Due Second Anniversary | 20,000 | ||||||||||
Contractual Obligation, Due Third Anniversary | 40,000 | ||||||||||
Contractual Obligation, Due Fourth Anniversary | 60,000 | ||||||||||
Contractual Obligation, Due Fifth Anniversary | 80,000 | ||||||||||
Contractual Obligation, Due Sixth Anniversary | 100,000 | ||||||||||
Patent and Technology License Agreement [Member] | Minimum Annual Royalty [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Contractual Obligation, Due in Next Fiscal Year, After Product Approval | 200,000 | ||||||||||
Contractual Obligation, Due in Second Year, After Product Approval | 400,000 | ||||||||||
Contractual Obligation, Due in Third Year, After Product Approval | $ 600,000 | ||||||||||
Patent and Technology License Agreement [Member] | Letter Agreement [Member] | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Payments for Other Fees | $ 691,186 |